ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, cilt.16, ss.128-131, 2025 (ESCI)
Tumor necrosis factor-alpha (TNF-alpha) inhibitors are biological agents frequently used in many clinics, especially in rheumatology. In this article, we report a 59-year-old woman with RA who received adalimumab treatment for five years. The diagnosis and treatment of miliary tuberculosis secondary to irregular latent tuberculosis (TB) treatment with atypical symptoms will be discussed. In the literature, patients with a similar diagnosis who developed TB during treatment have also been presented. Patients at risk of latent TB who receive anti-TNF therapy should be closely monitored and the importance of prophylaxis should be emphasized.